Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

Updated November 5th, 2021

Major Advance: PARP Inhibitor Pill Extends Life For Women With High Risk Breast Cancer & BRCA Mutations

A major new study has found that for women with early stage breast cancer classified as (HER2)–negative, who also have one of the mutations from the BRCA gene, a relatively new class of drugs called PARP Inhibitors significantly extends life after initial treatment.

NOW
PLAYING
For Advanced Lung Cancer With the EGFR Mutation, the Drug Tagrisso & Chemotherapy Extends Life
NOW
PLAYING
Sports Illustrated Swimsuit Model, 44, Who Posed With Cancer Surgery Scars Says 'Stop Taking Life For Granted And Instead Grab It By The Horns'
NOW
PLAYING
Toby Keith Admits 'Cancer's a Rollercoaster,' But He Won't Let Stage 4 Stomach Cancer Define Him
NOW
PLAYING
58% Drop In Breast Cancer Death Rate: Why Katie Couric, 67, And So Many Women Are Now Beating Breast Cancer
NOW
PLAYING
Remembering Actress Suzanne Somers, Who Battled Breast Cancer, As 'Step By Step' Cast Reunion Coming Soon: 'You Made Quite a Ripple My Friend Thank You'
NOW
PLAYING
Pluvicto Provides Hope For Veterans with Metastatic Prostate Cancer

SurvivorNetTV.
Hope. Science.
Inspiration.

WATCH NOW

Patient Pathfinder:

Clinical Trial Finder

Are you looking for other treatment options?
Right now there are ... breast cancer trials in the U.S. within 100 miles of

Enter your zip code and travel distance to explore trials in your area...

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.